Every 8-K that Traws Pharma, Inc. (TRAW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. reported Q2 2026 results, highlighting continued investment in its antiviral pipeline and a more constrained balance sheet. For the quarter ended June 30, 2026, the company generated no revenue versus $2.7 million a year earlier, reflecting the absence of prior-period deferred revenue tied to a terminated oncology license. It reported a net loss of $3.1 million, or $0.16 per basic and diluted share, compared with a $0.9 million loss, or $0.11 per share, in Q2 2025.
For the first half of 2026, Traws recorded a net loss of $10.2 million, versus net income of $20.6 million in the first half of 2025, when results included a $26.7 million non-cash gain from changes in warrant liabilities. As of June 30, 2026, cash and cash equivalents were $5.0 million, up from $3.8 million at year-end, and total stockholders’ equity was $1.7 million versus a deficit of $0.6 million at December 31, 2025. Management expects existing cash plus anticipated at-the-market equity proceeds to fund operations into the first quarter of 2027, but indicates additional financing may be required thereafter.
Operationally, the company is advancing tivoxavir marboxil (TXM), an oral prophylactic candidate for seasonal and pandemic influenza, and working to address regulatory feedback. It plans to resubmit an updated toxicology package to the UK MHRA by the end of Q3 2026 to enable a Phase 2a human influenza challenge study at hVIVO, while also preparing a comprehensive response to resolve the FDA clinical hold on the US IND with a goal of advancing the program in the United States by the end of 2026. In April 2026, Traws closed a financing providing $10.0 million upfront and potential access to up to $50.0 million through milestone-based warrant tranches linked to MHRA approval and challenge-study data.
Traws Pharma, Inc. reported that on July 29, 2026 it received a notification letter from the Nasdaq Listing Qualifications Department stating that its common stock is not in compliance with the Nasdaq Capital Market minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), because the closing bid price has been below $1.00 per share for at least 30 consecutive business days. The notice does not immediately affect the company’s Nasdaq listing.
Traws Pharma has 180 calendar days, until January 25, 2027, to regain compliance, which requires a closing bid price at or above $1.00 per share for at least 10 consecutive business days, a period Nasdaq may extend to up to 20 days. If compliance is not regained, Nasdaq may grant a second 180‑day grace period if other listing standards are met and the company plans to cure the deficiency. Otherwise, the stock may be subject to delisting, which the company could appeal. Traws Pharma states it will monitor its bid price and consider options, but there is no assurance of regaining compliance.
Traws Pharma, Inc. describes its ability to sell shares of common stock under an existing at-the-market equity offering program. Under a new prospectus supplement dated July 10, 2026, the company may offer and sell shares with an aggregate offering price of up to $5,575,709 through Citizens JMP Securities, LLC, reflecting its current “baby shelf” limitation under General Instruction I.B.6 of Form S-3. This activity is conducted pursuant to an at-the-market offering agreement that permits sales of up to $50,000,000 in total and relies on an effective shelf registration statement on Form S-3 declared effective on July 9, 2026.
Traws Pharma, Inc. reported the results of its 2026 annual stockholder meeting and related governance approvals. Stockholders approved an amendment to the 2021 Incentive Compensation Plan that increases the shares available for equity awards by 2,000,000, effective July 8, 2026. They also re-elected seven directors, ratified KPMG LLP as auditor for the year ending December 31, 2026, and approved the issuance of common shares upon exercise of Series B and Series C warrants issued under an April 15, 2026 Securities Purchase Agreement, as required by Nasdaq Listing Rule 5635(d). A proposal to permit adjournment of the meeting, if needed, was approved but not used because all key proposals passed.
Traws Pharma, Inc. is preparing an updated toxicology data package for tivoxavir marboxil to address information requests from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). The company expects to resubmit this package in the third quarter of 2026 to allow a planned Phase 2a human influenza challenge study in healthy volunteers to proceed.
Management believes the study could provide important proof-of-concept data for tivoxavir marboxil as an oral prophylaxis for seasonal influenza. Traws notes that tivoxavir marboxil has shown broad in vitro activity across multiple seasonal influenza strains and a pharmacokinetic profile consistent with chemoprophylactic use, and it plans to profile additional molecules in its influenza treatment program.
Traws Pharma, Inc. reported that its planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred after a negative review by the UK Medicines and Healthcare Products Regulatory Agency. This pushes back clinical evaluation of its lead long-acting influenza antiviral in humans.
The company emphasizes that TXM previously showed potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile suited for bird flu treatment and prevention. Management stresses that influenza antivirals remain a high priority and notes a cash runway extending to Q1 2027 as it advances backup influenza candidates with similar antiviral and pharmacokinetic characteristics but designed to avoid potential regulatory concerns.
Traws Pharma, Inc. reported a corporate update highlighting a new antiviral program targeting ongoing Hantavirus and Ebola Virus Disease outbreaks. The company is advancing a proprietary broad-spectrum oral combination that uses a novel “dual-strike” mechanism acting on host cell pathways, with both components already evaluated for safety in prior human studies as single agents. Non-clinical work is underway in validated Hantavirus and Ebola animal models conducted in Biosafety Level 3 and 4 laboratories, while chemical development and manufacturing are being scaled to support rapid deployment and potential stockpiling by health agencies. Traws is also engaging with organizations such as the CDC, Nigeria’s NAFDAC and the African Medicines Agency to support fast-track development and regional access, alongside its existing clinical-stage programs, including tivoxavir marboxil for influenza prevention and treatment and other investigational antivirals like ratutrelvir for COVID‑19.
Traws Pharma, Inc. reported that it may sell additional shares of common stock through its existing at-the-market equity program with Citizens JMP Securities, LLC. Under updated prospectus supplements, the company can offer shares having an aggregate offering price of up to $3,128,399, reflecting its current “baby shelf” limitation under General Instruction I.B.6. of Form S-3.
These sales would occur from time to time under the previously established At The Market Offering Agreement for up to $50,000,000 and rely on the company’s effective shelf registration statement on Form S-3 and related prospectus supplements.
Traws Pharma, Inc. reported Q1 2026 results showing a net loss of $7.1 million, or $0.53 per basic and diluted share, compared with net income of $21.5 million a year earlier, largely reflecting changes in warrant liability and higher R&D spending.
Revenue was $0.0 million versus $57,000 in Q1 2025. Research and development expense rose to $4.9 million from $2.5 million, while general and administrative expense declined to $2.0 million from $2.8 million.
The company highlighted an up to $60 million private investment in public equity, including $10 million received at closing and additional potential proceeds from milestone-based and three-year warrants, which together with existing cash are expected to fund operations, including a human influenza challenge trial for tivoxavir marboxil, into Q1 2027.
Traws Pharma reported 2025 results showing a sharp turnaround to net income of $9.2 million, or $0.83 per basic share, compared with a net loss of $166.5 million in 2024, largely reflecting the absence of prior-year acquired R&D expense and a favorable change in warrant liability.
Revenue rose to $2.8 million from $0.2 million, while R&D and G&A expenses were $12.1 million and $8.5 million, respectively. Cash and cash equivalents were $3.8 million as of December 31 2025. The company completed a private financing of up to $60 million, including $10 million upfront and additional milestone-based warrants, which together with existing cash is expected to fund operations, including a Phase 2a human influenza challenge trial for tivoxavir marboxil, into Q1 2027. Traws also highlighted positive Phase 2a topline data for ratutrelvir in COVID-19.
Traws Pharma, Inc. entered into a private investment in public equity financing, raising approximately $10 million in upfront gross proceeds and issuing common stock or pre‑funded warrants plus three series of common stock warrants. The warrants could provide up to an additional $50 million in gross proceeds if fully exercised for cash.
The financing is priced at $1.6730 per share (or $1.6630 per pre‑funded warrant) and is intended to fund a Phase 2a human challenge trial for the company’s influenza program in the United Kingdom. Series A, B and C warrants cover up to 29,914,595 shares in total and are exercisable upon specified regulatory, shareholder and market milestones.
Traws Pharma, Inc. filed an 8-K after completing analysis of a 90-patient, open-label Phase 2 study of oral ratutrelvir versus PAXLOVID® in mild-to-moderate COVID-19, including a PAXLOVID®-ineligible arm. PAXLOVID®-ineligible patients on ratutrelvir reported fewer treatment-related adverse events (10% vs 23.3%) and faster symptom resolution (HR 1.31; 95% CI 0.78–2.20; p=0.018), with no viral rebound observed in ratutrelvir-treated patients.
The company also reported that a tablet formulation of tivoxavir marboxil increased exposure by 30% versus a prototype, with modeling suggesting 28-day influenza protection and plans for a prophylaxis challenge study. Separately, the FDA placed the U.S. IND for tivoxavir marboxil on clinical hold over mutagenicity data, with formal feedback expected by March 16, 2026.
Traws Pharma, Inc. reported that it has completed an ongoing study of ratutrelvir, a ritonavir-free potential treatment for mild-to-moderate COVID-19 in both PAXLOVID-eligible and ineligible patients. The company also outlined plans to pursue an additional indication for its antiviral tivoxavir marboxil as a prophylactic treatment for seasonal influenza. These updates were provided in a press release attached as Exhibit 99.1, which also includes forward-looking statements that the company cautions are subject to significant risks and uncertainties that could cause actual results to differ from current expectations.
Traws Pharma, Inc. filed a Form 8-K to highlight a new regulatory and clinical update in its COVID-19 pipeline. The company issued a press release announcing that it has filed a U.S. Investigational New Drug Application with the Food and Drug Administration for tivoxavir marboxil, a potential treatment candidate. The same press release also provides updated results from an ongoing study of ratutrelvir, described as a ritonavir-free treatment being evaluated in both PAXLOVID®-eligible and ineligible patients with mild-to-moderate COVID-19. The press release is attached as an exhibit to the filing, and the company includes standard cautionary language about forward-looking statements and the risks and uncertainties around future results.
Traws Pharma, Inc. filed a current report describing that it issued a press release announcing positive interim data from its Phase 2 study of ratutrelvir, a ritonavir-free treatment, in newly diagnosed COVID subjects. The filing emphasizes that these results are preliminary and accompanied by customary forward-looking statements language, highlighting that actual outcomes may differ due to various risks and uncertainties. The press release with additional details is included as an exhibit.
Traws Pharma, Inc. granted new stock options and restricted stock units to its executive leadership on December 12, 2025. Grants include 147,771 options and 36,943 RSUs for CEO Iain Dukes, 61,571 options and 15,393 RSUs for CFO Charles Parker, 73,886 options and 18,471 RSUs for Chief Science Officer C. David Pauza, and 65,676 options and 16,419 RSUs each for Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk. The options have a $2.33 per share exercise price (the closing price on December 12, 2025), a ten-year term, and vest in full on the first anniversary of the grant date, subject to continued service, with all awards granted under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma (TRAW) furnished an update on November 13, 2025 announcing it issued a press release with financial results for the quarter ended September 30, 2025 and began using a new corporate presentation. Both materials were provided as Exhibits 99.1 and 99.2.
The materials under Item 7.01 are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced. The company also included standard forward-looking statements language.
Traws Pharma (TRAW) reported executive equity grants. On October 12, 2025, the board’s Compensation Committee approved stock options for five executives at an exercise price of $3.01 per share, each with a 10‑year term and one‑year cliff vesting (vesting in full on the first anniversary, subject to continued service). Grants include 64,839 options to the CEO, and 32,406 each to the CFO, Chief Science Officer (Virology), and Chief Medical Officer, plus 22,435 to the COO. Awards were made under the Amended and Restated 2021 Incentive Compensation Plan.
Traws Pharma (TRAW) announced a clinical milestone via an 8-K: on October 14, 2025, the company dosed the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment candidate for newly diagnosed COVID subjects. The company furnished a press release as Exhibit 99.1.
This update signals progression into mid-stage testing for ratutrelvir, with details provided in the accompanying press release.
Traws Pharma, Inc. filed an 8-K describing board and leadership updates. On October 1, 2025, the Board appointed John Leaman, MD as an independent director with a term expiring at the 2025 annual meeting of stockholders, and added him to the Audit Committee. His compensation will match that of other non-employee directors under the company’s disclosed director pay program, and there are no related-party arrangements or transactions noted in connection with his appointment.
The Board also removed the “interim” designations from the titles of Dr. Iain Dukes and Charles Parker, who now serve as Chief Executive Officer and Chief Financial Officer, respectively. Mr. Parker continues to provide CFO services as a non-employee consultant through Stout, for which the company pays $500 per hour, up to a maximum of $50,000 per month. A press release dated October 6, 2025, was furnished as an exhibit.
Traws Pharma, Inc. filed a current report to highlight new investor communications and a clinical milestone. The company has begun using a new corporate presentation, which is furnished as an exhibit and posted on its website.
The report also notes a press release announcing that a Human Research Ethics Committee has approved proceeding with a Phase 2 study of ratutrelvir, a ritonavir-free treatment in newly diagnosed COVID subjects. The press release and the investor presentation are attached as Exhibits 99.1 and 99.2.
Traws Pharma, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025, and began using a new corporate investor presentation. The earnings release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2, and the presentation will be posted on the company website.
The disclosure in Item 7.01 is incorporated by reference into Item 2.02 but is explicitly furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless specifically referenced. The Current Report and its exhibits include customary forward‑looking statements and a risk disclaimer. The 8‑K body does not contain numeric financial results; investors must review Exhibits 99.1 and 99.2 for the full figures and context.